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TNFa depleting therapy improves fertility
and animal welfare in TNFa-driven
transgenic models of polyarthritis when
administered in their routine breeding
Amy J. Naylor1, Guillaume Desanti1, Atif N. Saghir1 and
Rowan S. Hardy1,2,3
Abstract
Transgenic tumour necrosis factor alpha (TNFa)-driven models of polyarthritis such as the TNFARE mouse
have proven to be invaluable in delineating aspects of inflammatory disease pathophysiology in humans.
Unfortunately, the onset of joint destruction and inflammation in these models represents a significant det-
riment to breeding management. We examined whether TNFa depleting therapy ‘infliximab’ might represent a
significant refinement in routine breeding. Clinical scores of joint inflammation were assessed in TNFARE
males receiving either infliximab (10 mg/kg) or saline by twice-weekly intraperitoneal injection. Joint histology
and bone morphology were assessed by histological analysis and micro-computed tomography (CT), respect-
ively. Analysis of breeding was examined retrospectively in TNFARE males prior to, and following, regular
introduction of infliximab. Clinical scores of inflammation were significantly reduced in TNFARE males
receiving infliximab (control 6.6 arbitrary units [AU] 0.88 versus infliximab 4.4 AU 1.4; P< 0.05), while
measures of pannus invasion and bone erosion by histology and micro-CT were markedly reduced. In the
breeding groups, TNFARE males receiving infliximab injections sired more litters over their breeding lifespan
(control 1.69 0.22 versus infliximab 3.00 0.19; P< 0.005). Furthermore, prior to infliximab, TNFARE males
had a 26% risk of failing to sire any litters. This was reduced to 7% after the introduction of infliximab. This
study is the first to report that regular administration of infliximab is effective at suppressing disease activity
and improving animal welfare in TNFARE animals. In addition, we have shown that infliximab is highly effi-
cacious in improving breeding behaviour and increasing the number of litters sired by TNFARE males.
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Rheumatoid arthritis (RA) is a chronic auto-
immune inﬂammatory disease resulting in polyarticular
inﬂammation, joint destruction and systemic
inﬂammatory complications. Murine models of polyar-
thritis closely model features of RA in humans and
have proven to be eﬀective in advancing our under-
standing of the pathophysiology of inﬂammatory
disease.
The primacy of murine models of inﬂammatory dis-
ease is underpinned by several key factors: parallels
between the immune responses, their highly conserved
genetic background, high progeny numbers, and short
breeding times that have enabled their extensive use
and validation in medical research.1
A range of transgenic murine models of spontaneous
polyarthritis exist, including the hTNFtg, TNFARE,
KBxN, SKG and DNase II mice.2–6 These models
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oﬀer several advantages relative to inducible models,
the major beneﬁts being the strong parallels with
chronic inﬂammatory disease in humans and develop-
ment of polyarthritis in a highly reproducible and tem-
porally-controlled manner, making them ideal for
examining therapeutic disease interventions. Indeed,
in the seminal study by Keﬀer et al., a once-weekly
injection of inﬂiximab completely abrogated disease
activity in hTNFtg mice, contributing to the now com-
monplace application of biological anti-tumour necro-
sis factor alpha (TNFa) therapies as a gold standard in
the treatment of chronic inﬂammatory disease.2,7,8
The hTNFtg model (known as Tg(TNF)197Gkl)
possesses an insertion of a 30-modiﬁed human TNF
transgene which greatly increases TNFa mRNA stabil-
ity resulting in systemic overproduction of human
TNFa.2 In the TNFARE mouse, the 30 untranslated
region (UTR) of the AU-rich element (ARE) in the
murine TNFa gene is deleted, resulting in greatly
increased TNFa mRNA stability and systemic overex-
pression.6 As a consequence, inﬂammation is driven by
the overexpression of TNFa in all major tissues result-
ing in polyarthritis and joint destruction in both
models. In addition, the TNFARE mouse presents
with an inﬂammatory intestinal pathology that closely
models inﬂammatory bowel disease as well as occa-
sional mild inﬂammation in the liver and the lung.
These models have helped in delineating the patho-
physiology of inﬂammatory diseases such as RA in
humans, demonstrating the role that TNFa plays at
the apex of a pro-inﬂammatory cytokine cascade, med-
iating leukocyte inﬁltration, synovitis and joint
destruction.9
One notable drawback associated with the use of
transgenic models of polyarthritis occurs in maintain-
ing breeding colonies required to generate experimental
animals. Both hTNFtg and TNFARE mice are bred
using a heterozygous transgenic male crossed with a
wild-type female to generate oﬀspring with a 50% inci-
dence of developing spontaneous polyarthritis. While
required in experimental animals, the spontaneous
onset of polyarthritis and systemic inﬂammation in
breeding males is of signiﬁcant detriment to their wel-
fare and breeding success.10
From 2–4 weeks of age, heterozygous TNFARE
mice present with early signs of inﬂammatory lesions
within the terminal ileum and proximal colon and
become more severe around eight weeks. The histo-
logical and clinical onset of polyarthritis is detected
between 6 and 8 weeks in TNFARE mice and becomes
increasingly severe up to 14 weeks. Following onset of
arthritis, animals are scored for joint inﬂammation, as
well as behaviour, mobility, weight loss and grimace.6
A number of welfare measures, as outlined by Hawkins
et al., are observed in the maintenance of these
transgenic animals to mitigate these factors and
enhance breeding. These include soft litter to reduce
pain on walking, non-tangling nesting material and
eﬀortless access to food and water to cater for
disability. Lastly the introduction of opiate pain relief
is utilized where arthritis is evident to minimize pain and
distress, given once daily at ﬁrst onset (0.1mg/kg sub-
cutaneous buprenorphine).11,12 Ultimately, the intro-
duction of clearly deﬁned humane endpoints for
articular inﬂammation scores (supplementary Table 1,
see http://lan.sagepub.com for all supplementary mater-
ial), and clinical scores of weight loss, behaviour, mobil-
ity, grimace, severity and duration of joint inﬂammation
(supplementary Table 2), ensure that breeding males do
not experience excessive distress or pain. Unfortunately,
this reduces their breeding lifespan to around 14–18
weeks, relative to 35–40 weeks in wild-type animals.
Inﬂiximab is a neutralizing and depleting antibody
targeted at human TNFa, and is successfully used to
ameliorate joint destruction and inﬂammation in
hTNFtg mice.13,14 Interestingly, while inﬂiximab is not
reported to have cross reactivity with murine TNFa
(which drives polyarthritis in the TNFARE model),
the reported suppression of inﬂammation and TNFa
in murine models of colitis and diabetes suggest further
modes of action.15–19 Therefore, given the central role of
TNFa in the pathophysiology of the TNFARE model,
we examined whether a similar regimen of regular inﬂix-
imab injections would improve management of our het-
erozygous TNFARE breeding programmes.
Consequently, in this study we show that regular
administration of inﬂiximab to breeding TNFARE
males provided a signiﬁcant reﬁnement in the breeding
programme, improving animal welfare by suppressing
disease activity and reducing the numbers of breeding
animals required to generate experimental TNFARE
animals.
Materials and methods
Animals
C57BL/6 TNFARE mice were obtained from
Dr George Kollias (BSRC Fleming, Athens, Greece).6
At 6–8 weeks, heterozygous TNFARE male mice
(TNFARE/þ, later referred as TNFARE) developed
clinical signs of systemic polyarthritis, with 100% pene-
trance. The mice were housed under controlled envir-
onmental conditions (20.2 2C, 14:10 h light:dark
cycle). The experiments were carried out following
strict guidelines governed by the UK Animal
(Scientiﬁc Procedures) Act 1986 and approved by the
Birmingham Ethical Review Subcommittee. Only male
animals were utilized for the examination of polyarthri-
tis and breeding.
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TNFARE transgenic mouse model and
clinical scoring
Preparations of inﬂiximab (Remicade; Janssen
Biotech, Horsham, PA, USA) were reconstituted at
10mg/mL in sterile water according to the manufac-
turer’s guidelines. To assess the eﬀects of inﬂiximab
on disease activity, TNFARE males from six weeks
of age were given either 10mg/kg of inﬂiximab or
saline (100 mL of 0.9% NaCl in distilled water) by
twice-weekly intraperitoneal injection. For scoring
joint inﬂammation and polyarthritis, inﬂiximab injec-
tions were split to ensure that within any one litter, one
male TNFARE sibling would receive inﬂiximab and
one would receive the saline control. Animals were
then scored separately in a blinded manner.
TNFARE animals were caught by their tail, lifted
with hand support and immediately transferred onto
a metallic cage to minimize involuntary extension/ﬂex-
ion of arthritic joints. They were then restrained by the
back and lifted to perform paw monitoring. The ani-
mals were familiarized with handling and observation
for one week prior to the onset of experiments to min-
imize stress. All injections were performed on Tuesdays
and Fridays in the afternoon by a trained member of
staﬀ. Upon starting inﬂiximab the mice were scored
three times weekly (Monday, Wednesday and Friday)
for inﬂammatory joint scores (supplementary Table 1)
and collective clinical scoring of weight loss, behaviour,
mobility, grimace, severity and duration of joint inﬂam-
mation (supplementary Table 2) as previously
reported.20
At 14 weeks old the animals were culled and their
hindlimbs were collected for histology and micro-com-
puted tomography (CT) analysis.
TNFARE transgenic mouse breeding
programme
A retrospective analysis of breeding was performed in
17 breeding pairs prior to the introduction of inﬂiximab
and in 14 breeding pairs following the regular intro-
duction of inﬂiximab. Breeding pairs consisted of a
C57BL/6 TNFARE male and a C57BL/6 wild-type
female paired at six weeks of age. In each breeding
pair, the number of successfully weaned litters during
their breeding lifespan, average litter size, numbers
of male and female pups per litter, litters that
failed to progress through weaning, and breeding
pairs that failed to produce a litter were recorded.
Breeding outputs were compared with a C57BL/6
wild-type colony consisting of 10 breeding pairs, moni-
tored between six and 26 weeks, at a time point
matched to TNFARE animals prior to the introduction
of inﬂiximab.
Micro-CT
The hindlimbs were isolated post-mortem and imaged
with a SkyScan 1172 micro-CT scanner (Bruker,
Kontich, Belgium) using X-ray beam settings of 60 kV
source voltage and 167 mA source current. Projections
were taken every 0.45 at 600ms exposure, with an
image pixel size of 13.59mm. Image volumes were
reconstructed using the Feldkamp algorithm (NRecon
1.6.1.5; Bruker), having applied beam hardening cor-
rection. A radiodensity range of –300 to 3000 HU
was chosen to isolate the bony structures from the ima-
ging medium. CTAnalyser 1.12 software (SkyScan) was
used to extract an isosurface mesh representation of the
reconstructed micro-CT slices. MeshLab 1.3.2 (an open
source software developed with the support of the 3D-
CoForm project) was used to modify the raw meshes,
and the samples were shaded in MeshLab using ambi-
ent occlusion.
Meshes were visualized in MeshLab and scored
blind by three independent researchers as follows.
Meshes were divided into three regions, ‘heel’ (com-
prising the calcaneus, centrale, distal tarsals, tibiale
and talus but excluding the tibia and ﬁbula), ‘metatar-
sals’ and ‘phalanges’ (excluding the claws). Each
region was scored separately for the degree of erosion:
0¼ normal, 1¼ roughness, 2¼pitting, 3¼ full thick-
ness holes. A score was also given to describe the
extent of the area aﬀected: 0¼ none, 1¼ a few
small areas, 2¼multiple small–medium sized areas,
3¼multiple medium–large areas or extensive. The
two scores were then multiplied together for each
region, and then summed to give a maximum score
per paw of 27.
Histological analysis
Following decalciﬁcation in 0.5M EDTA (pH 8.0),
histological analysis was performed on paraﬃn-
embedded 10 mm sections of hindlimbs taken from
either wild-type or TNFARE animals receiving inﬂix-
imab or saline injections. The sections were stained with
haematoxylin and eosin prior to quantitative analysis
of the pannus size at the metatarsal–phalangeal joint
interface using ImageJ software (NIH, Bethesda, MD,
USA). Pannus size in arbitrary units (AU) was
calculated from the region of synovial pannus, clearly
visible by histology (as depicted within supplementary
Figure 1), and invading into the subchondral bone of
the ﬁrst proximal phalanges at the metatarsal–phalan-
geal joint interface. Three adjacent 10 mm sections were
cut from the centre of the joint, and the pannus size was
determined as described above to generate a mean
value.
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Statistical analysis
To detect a 40% decrease in joint inﬂammation scores
four experimental animals were required per group (cal-
culated using in-house preliminary data in TNFARE
mice at week 14; score 6.6, standard deviation [SD] 1.7,
power 0.8, alpha 0.05). Unless stated otherwise, data
shown are mean standard error (SE) of the mean of
four wild-type control animals or four TNFARE ani-
mals receiving saline and ﬁve animals receiving inﬂixi-
mab. Statistical signiﬁcance was deﬁned as P< 0.05
(*P< 0.05; **P< 0.005; ***P< 0.0005) using either
an unpaired Student’s t-test or a two-way analysis of
variance (ANOVA) with a Tukey post hoc analysis
where a Gaussian distribution was identiﬁed or deter-
mined using a non-parametric Kruskal–Wallis test with
a Dunn’s multiple comparison where it was absent.
Results
Infliximab suppresses disease activity
in TNFARE mice
Clinical signs of joint inﬂammation were evident in
both saline- and inﬂiximab-treated mice from six
weeks of age, but were signiﬁcantly reduced in the
group receiving inﬂiximab at eight weeks of age
(Figure 1a). Joint inﬂammation scores remained signiﬁ-
cantly lower in the inﬂiximab group relative to the
saline group up to 14 weeks. When combined clinical
scores measuring severity of inﬂammation, duration of
inﬂammation, mobility, behaviour, weight and grimace
were assessed, a similar pattern was observed, with
increased scores being evident in saline-treated animals
from eight weeks (Figure 1b). Once again, this pattern
continued up to 14 weeks.
In this study, progressive weight loss provides an
eﬀective readout of the degree of systemic inﬂamma-
tion. Consequently, weight loss of greater than 20%
also represents an eﬀective humane endpoint in
TNFARE mice. TNFARE animals receiving saline
only, developed evidence of weight loss at day 70, plat-
eauing from day 77. This was in contrast to progressive
weight gain observed throughout the inﬂiximab-treated
TNFARE animals and wild-type counterparts
(Figure 1c). Consequently, TNFARE animals receiving
inﬂiximab maintained a normal body weight relative to
control animals throughout the monitoring period
(Figure 1c).
Together, these data demonstrate that TNFARE
animals receiving regular injections of inﬂiximab,
while not completely protected from the detrimental
eﬀects of TNFa excess, present with a markedly
milder phenotype than untreated counterparts. This is
evidenced by their signiﬁcant reduction in clinical
scores of joint inﬂammation, improved mobility,
behaviour and grimace and improved body weights
relative to TNFARE animals receiving saline only.
Therefore, the administration of inﬂiximab represents
a signiﬁcant reﬁnement in regard to improving animal
pain and welfare in the long-term maintenance of these
animals.
Infliximab protects against joint destruction
While scoring of inﬂammation and clinical features of
disease provide valuable insight into observable meas-
ures of disease activity, they are limited in their ability
to assess quantiﬁable measures of direct joint destruc-
tion. To gain a more comprehensive understanding of
how administration of inﬂiximab directly inﬂuences the
Figure 1. Scoring of (a) joint inflammation, (b) clinical scoring (weight, inflammation, grimace, behaviour, mobility,
inflammation severity and duration), (c) total body weights in wild-type (WT) or TNFARE animals receiving either
twice-weekly intraperitoneal injections of saline or infliximab at 10 mg/kg. Values are expressed as mean standard error
of four WT animals, five TNFARE animals receiving infliximab and four TNFARE animals receiving saline. Statistical
significance was determined using one-way analysis of variance (ANOVA) with a Tukey’s post hoc analysis. *P< 0.05,
**P< 0.005.
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process of joint destruction we examined three-dimen-
sional reconstructions of joints using micro-CT, and
assessed joint histology of TNFARE animals receiving
either saline or inﬂiximab.
Analysis of cortical bone erosion by micro-CT
within ex vivo hind paws of TNFARE animals receiv-
ing saline only, revealed signiﬁcant full thickness holes
in the talus, intermedium and centrale with marked
pitting and roughness of the distal tarsals relative to
their wild-type counterparts. By contrast full thickness
cortical holes and pitting were signiﬁcantly reduced in
TNFARE animals receiving inﬂiximab (Figure 2b).
Quantiﬁcation of erosions revealed a strong trend
towards reduced scores in TNFARE animals receiving
inﬂiximab relative to those receiving saline which,
unlike TNFARE animals, were not signiﬁcantly greater
than wild-type controls (Figure 2d).
The mice receiving regular inﬂiximab injection dis-
played a marked reduction in inﬂammatory pannus in
the metatarsal–phalangeal joint interface (Figure 2a).
When the pannus invading within the subchondral
bone was quantiﬁed, pannus size was found to be sig-
niﬁcantly reduced in TNFARE mice receiving inﬂixi-
mab relative to those receiving saline (Figure 2c).
These data demonstrate that TNFARE animals
receiving inﬂiximab have a signiﬁcant reduction in
joint inﬂammation and destruction relative to those
receiving saline only. Similarly, local bone erosions
and destruction of juxta articular bone within
inﬂamed joints are also signiﬁcantly reduced in
TNFARE animals receiving inﬂiximab. These data
directly support clinical scoring of joint inﬂammation
and conﬁrm that inﬂiximab signiﬁcantly retards the
disease process that underpins deformity, loss of func-
tion and joint pain.
Infliximab increases litter numbers and
breeding behaviour in TNFARE mice
To examine the impact of the introduction of inﬂiximab
on breeding behaviour and breeding output, we retro-
spectively examined 17 TNFARE breeding pairs from
a time point prior to the introduction of inﬂiximab
injections, and 14 TNFARE breeding pairs following
the introduction of inﬂiximab injections.
The ﬁndings (Table 1) clearly demonstrated that
TNFARE males receiving regular inﬂiximab injections
sired more litters over their breeding lifespan.
Furthermore, when compared with wild-type control
breeding pairs on a C57BL/6 background (Table 2),
there was a signiﬁcant decrease in the percentage of
TNFARE males successfully siring a litter. By contrast,
no signiﬁcant diﬀerences were identiﬁed in TNFARE
males successfully siring a litter following the introduc-
tion of inﬂiximab. Prior to the introduction of
inﬂiximab injections no TNFARE males reached the
26-week breeding lifespan due to humane endpoints
being exceeded. By contrast, following the introduction
of inﬂiximab all except three breeding males achieved a
26-week breeding lifespan (data not shown).
These data demonstrate clear beneﬁts of regular
administration of inﬂiximab in breeding TNFARE ani-
mals, resulting in greater numbers of litters over their
breeding lifespan, a greater chance of siring a litter, and
trends towards larger litter sizes and greater chances of
litters surviving past weaning. Consequently, fewer
breeding pairs are required to generate experimental
animals, allowing a signiﬁcant reduction in TNFARE
breeding animals needed to maintain a breeding
programme.
Discussion
Transgenic, spontaneous mouse polyarthritis models
are widely used within the rheumatology research
community. Unfortunately, one signiﬁcant drawback
in their use in medical research arises through
reduced animal welfare as a result of systemic inﬂam-
mation in breeding animals used to generate experi-
mental animals. While the 100% penetrance of
disease symptoms in animals carrying a disease trans-
gene is a beneﬁt in helping to reduce experimental
animal numbers, it is a detriment in breeding pro-
grammes where it suppresses breeding behaviour,
increases pain and distress and ultimately reduces
breeding lifespans of animals.
In this study we have explored whether the bio-
logical anti-human TNFa drug inﬂiximab may prove
eﬃcacious in improving animal welfare and breeding
behaviour in male TNFARE mice. Inﬂiximab has pre-
viously been shown to be highly eﬃcacious in abrogat-
ing disease activity and joint destruction in the hTNFtg
mouse when given once weekly at 8mg/kg by intraper-
itoneal injection, and is routinely administered in our
breeding programmes of these animals.2,20
While hTNFtg and TNFARE models of polyar-
thritis are driven by a common pathophysiology,
inﬂiximab is not reported to cross react with murine
TNFa.21 However, its eﬃcacy has been reported in
several murine models of chronic inﬂammation sug-
gesting further modes of action beyond direct neutral-
ization and depletion of TNFa.15–19 These include the
induction of T-cell apoptosis and suppression of
angiogenesis, possibly mediated via Fc-mediated inter-
actions and the natural immunogenicity of
inﬂiximab.21–24
Therefore, we predicted that inﬂiximab may prove
eﬀective in suppressing disease activity in TNFARE
animals in an identical manner as reported in hTNFtg
mice.25 Previous studies using inﬂiximab in mice have
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demonstrated that it is well tolerated at levels of up
to 10mg/kg over a period of up to 24 weeks.26
Consequently, following consultation with the named
animal care and welfare oﬃcer and named veterinary
oﬃcer within our animal handling facility, we examined
whether twice-weekly 10mg/kg intraperitoneal
injections of inﬂiximab would improve animal welfare
and breeding in TNFARE animals.
We found that clinical scoring of joint inﬂammation,
duration of inﬂammation, mobility, behaviour and
body weight were all signiﬁcantly improved in
TNFARE animals receiving inﬂiximab relative to
Figure 2. (a) Representative paraffin-embedded sections from the metatarsal–phalangeal joint interface stained with
haematoxylin and eosin (scale bars 200 mm). (b) Representative images of 3D reconstructions of hind paws with increased
magnification at the ankle, using micro-computed tomography(CT). (c) Quantification of degree of pannus invasion in the
metatarsal–phalangeal joint interface (from haematoxylin and eosin histology). (d) Quantification of cortical erosion in the
bones of the ankle, metatarsals and phalanges from micro-CT in wild-type (WT) or TNFARE animals receiving either
twice-weekly intraperitoneal injections of saline or infliximab at 10 mg/kg. Values are expressed as mean standard error
of four WT animals, five TNFARE animals receiving infliximab and four TNFARE animals receiving saline. Statistical
significance was determined using one-way analysis of variance (ANOVA) with a Tukey’s post hoc analysis for pannus
invasion and Kruskal–Wallis test and Dunn’s multiple comparison for micro-CT quantification of erosions. Arrows denote
pannus adjacent to cortical bone in (a), and full thickness cortical bone erosions within (b). **P< 0.005, NS: not significant.
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those receiving saline alone. Unfortunately, as opposed
to administration of inﬂiximab in hTNFtg animals,
clinical signs of polyarthritis were still evident, indicat-
ing that regular inﬂiximab injections were unable to
completely abrogate host murine TNFa overexpres-
sion. Inﬂiximab was originally designed to target and
deplete human TNFa, and therefore may utilize alter-
native modes of action in suppressing disease activity in
inﬂammatory models driven by murine TNFa.
Therefore, it is unsurprising that inﬂiximab injections
are less eﬀective at suppressing disease in this model.
Despite this, it is clear that regular administration of
inﬂiximab signiﬁcantly suppresses polyarthritis disease
activity and improves animal welfare. This was more
evident when the structure of bone by micro-CT and
the histology of joints were examined, showing signiﬁ-
cantly reduced pannus invasion and bone erosions in
aﬀected joints.
While disease activity was not completely suppressed
in TNFARE animals receiving inﬂiximab, body
weights were markedly increased relative both to
those receiving saline only and to their wild-type coun-
terparts. Weight loss in TNFARE animals can in part
be attributed to malnutrition secondary to intestinal
inﬂammation. Whether the weight gain observed in
the inﬂiximab-treated group reﬂects the suppression
of inﬂammatory bowel disease-like symptoms cannot
be determined from this study without examining intes-
tinal pathology. This is further complicated, as rapid
weight loss is also an important measure of
Table 1. Mean (AVG) number of litters successfully weaned, mean number of pups generated per litter, mean number of
male and female pups per litter, percentage of litters that successfully survive beyond weaning and percentage of males
that successfully sire a litter in breeding pairs consisting of heterozygous TNFARE males and wild-type (WT) females over
periods preceding the introduction of regular infliximab injections, or following the regular introduction of twice weekly
intraperitoneal injections of infliximab at 10 mg/kg in breeding males.
TNFARE maleWT female
Pre infliximab Post infliximab
AVG SE AVG SE Significance
Litters weaned 1.69 0.22 3.00 0.19 0.0019
Total pups per litter 5.66 0.47 6.69 0.48 0.085
Males per litter 2.61 0.32 3.45 0.39 0.086
Female per litter 3.05 0.38 3.24 0.29 0.635
Litters successfully weaned (%) 74.13 8.65 93.46 1.28 0.0604
Successfully sire a litter (%) 70.60 14.87 85.72 9.70 0.282
Values are expressed as mean standard error (SE) from 17 breeding pairs where male TNFARE animals did not receive infliximab
injections versus 14 breeding pairs where male TNFARE animals received regular infliximab injections. Statistical significance was
determined using an unpaired student’s t-test for litter size and pups for litter and a Mann–Whitney U-test for percentage of litters
weaned and percentage successfully siring a litter.
Table 2. Mean (AVG) number of litters successfully weaned, mean number of pups generated per litter, mean number of
males and female pups per litter, percentage of litters that successfully survive beyond weaning and percentage of males
that successfully sire a litter in breeding pairs consisting of wild-type (WT) males and WT females over the periods
preceding the introduction of regular infliximab injections.
WT maleWT female
WT breeding
Versus TNFARE
Versus TNFARE/
infliximab
AVG SE Significance Significance
Litters weaned 3.80 0.39 0.0016 0.065
Total pups per litter 6.43 0.80 0.27 0.63
Males per litter 3.41 0.53 0.10 0.93
Female per litter 3.02 0.39 0.95 0.54
Litters successfully weaned (%) 86.77 10.16 0.883 0.178
Successfully sire a litter (%) 100 0.00 0.136 0.146
Values are expressed as mean standard error (SE) from 10 breeding pairs. Statistical significance was determined using an unpaired
student’s t-test for litter size and pups for litter and a Mann–Whitney U-test for percentage of litters weaned and percentage successfully
siring a litter.
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deteriorating health in cytokine-driven cachexia. TNFa
directly induces numerous catabolic pathways in mice
and humans, and also suppresses normal feeding
behaviour.27–29 Regardless of the underlying mechan-
ism, when combined with our observations with disease
activity and joint destruction, this study clearly demon-
strates that regular administration of inﬂiximab in
TNFARE animals represents a signiﬁcant reﬁnement
in their maintenance in breeding programmes, and
markedly improves animal welfare.
Retrospective examination of the impact of admin-
istration of inﬂiximab in TNFARE breeding males
demonstrated that it was highly eﬃcacious in improv-
ing breeding behaviour, increasing the number of litters
sired during their breeding lifespan and increasing the
percentage of males that successfully bred and sired
litters. In addition, non-signiﬁcant trends were
observed in the numbers of pups sired per litter, favour-
ing increased numbers of males per litter. This result
was perhaps unsurprising given that these mice survive
longer without exceeding the criteria for their humane
endpoints; and it also undoubtedly reﬂects an improve-
ment in animal welfare through reduced pain and dis-
tress – factors that are known to suppress mating
behaviour in male rodents.10
Taken together, these results clearly demonstrate
that the application of regular inﬂiximab injections in
TNFARE breeding males represents a signiﬁcant
reﬁnement in practice, allowing a reduction in animal
numbers required in routine breeding to generate
experimental animals.
A ﬁnal consideration should be whether regular
inﬂiximab administration would prove beneﬁcial in
other genetically manipulated models of spontaneous
polyarthritis, such as the KBxN, SKG and DNase II
mice. These models have varying involvement for
TNFa in their disease pathology, and so the beneﬁcial
eﬀects may vary greatly. Consequently, we propose
that its application in these models might merit
investigation.
Conclusions
This study is the ﬁrst to report that regular administra-
tion of inﬂiximab is eﬀective at suppressing disease
activity systemic inﬂammation and improving animal
welfare in TNFARE animals. In addition, we have
shown that inﬂiximab is highly eﬃcacious in improving
breeding behaviour and increasing the number of litters
sired by TNFARE males. Consequently, in both
hTNFtg and TNFARE mice, regular administration
of inﬂiximab in breeding males represents a reﬁnement
in routine maintenance and allows a signiﬁcant reduc-
tion of the numbers of breeding animals required to
generate experimental animals.
Acknowledgements
We would like to thank Professor George Kollias (Hellenic
Pasteur Institute, Athens, Greece) for providing the hTNFtg
and TNFARE mice; the Biomedical Services Unit (University
of Birmingham) for supporting animal experiments; and the
Department of Musculoskeletal Pathology (Robert Aitken
Institute, University of Birmingham) for embedding and cut-
ting tissue for histology.
Declaration of conflicting interests
The authors declared no potential conﬂicts of interest with
respect to the research, authorship, and/or publication of this
article.
Funding
This research was supported by Arthritis Research UK grants
(Reference: 19859 & 20843).
References
1. Shay T, Jojic V, Zuk O, et al. Conservation and divergence
in the transcriptional programs of the human and mouse
immune systems. Proc Natl Acad Sci USA 2013; 110:
2946–2951.
2. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice
expressing human tumour necrosis factor: a predictive gen-
etic model of arthritis. EMBO J 1991; 10: 4025–4031.
3. Kouskoff V, Korganow AS, Duchatelle V, Degott C,
Benoist C and Mathis D. Organ-specific disease provoked
by systemic autoimmunity. Cell 1996; 87: 811–822.
4. Kawane K, Ohtani M, Miwa K, et al. Chronic
polyarthritis caused by mammalian DNA that escapes
from degradation in macrophages. Nature 2006; 443:
998–1002.
5. Sakaguchi N, Takahashi T, Hata H, et al. Altered thymic
T-cell selection due to a mutation of the ZAP-70 gene
causes autoimmune arthritis in mice. Nature 2003; 426:
454–460.
6. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F
and Kollias G. Impaired on/off regulation of TNF biosyn-
thesis in mice lacking TNF AU-rich elements: implications
for joint and gut-associated immunopathologies. Immunity
1999; 10: 387–398.
7. Chu CQ, Field M, Feldmann M and Maini RN.
Localization of tumor necrosis factor alpha in synovial
tissues and at the cartilage–pannus junction in patients
with rheumatoid arthritis. Arthritis Rheum 1991; 34:
1125–1132.
8. Elliott MJ, Maini RN, Feldmann M, et al. Randomised
double-blind comparison of chimeric monoclonal anti-
body to tumour necrosis factor alpha (cA2) versus placebo
in rheumatoid arthritis. Lancet 1994; 344: 1105–1110.
9. Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki
M, Sawai T, et al. The role of TNF-alpha in the patho-
genesis of inflammation and joint destruction in rheuma-
toid arthritis (RA): a study using a human RA/SCID
mouse chimera. Rheumatology (Oxford) 2002; 41(3):
329–37.
8 Laboratory Animals 0(0)
10. Kirby ED, Geraghty AC, Ubuka T, Bentley GE and
Kaufer D. Stress increases putative gonadotropin inhibi-
tory hormone and decreases luteinizing hormone in male
rats. Proc Natl Acad Sci U S A 2009; 106(27): 11324–9.
11. Walker JS. Anti-inflammatory effects of opioids. Adv
Exp Med Biol 2003; 521: 148–160.
12. Hawkins P, Armstrong R, Boden T, et al. Applying
refinement to the use of mice and rats in rheumatoid
arthritis research. Inflammopharmacology 2015; 23:
131–150.
13. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic
efficacy of multiple intravenous infusions of anti-tumor
necrosis factor alpha monoclonal antibody combined
with low-dose weekly methotrexate in rheumatoid arth-
ritis. Arthritis Rheum 1998; 41: 1552–1563.
14. Maini R, St Clair EW, Breedveld F, et al. Infliximab
(chimeric anti-tumour necrosis factor alpha monoclonal
antibody) versus placebo in rheumatoid arthritis patients
receiving concomitant methotrexate: a randomised phase
III trial. ATTRACT Study Group. Lancet 1999; 354:
1932–1939.
15. Knight DM, Trinh H, Le J, et al. Construction and initial
characterization of a mouse–human chimeric anti-TNF
antibody. Mol Immunol 1993; 30: 1443–1453.
16. Yamakawa I, Kojima H, Terashima T, et al. Inactivation
of TNF-alpha ameliorates diabetic neuropathy in mice.
Am J Physiol Endocrinol Metab 2011; 301: E844–E852.
17. Kim YJ, Hong KS, Chung JW, Kim JH and Hahm KB.
Prevention of colitis-associated carcinogenesis with inflix-
imab. Cancer Prev Res (Phila) 2010; 3: 1314–1333.
18. Fries W, Muja C, Crisafulli C, et al. Infliximab and eta-
nercept are equally effective in reducing enterocyte
APOPTOSIS in experimental colitis. Int J Med Sci
2008; 5: 169–180.
19. Myrelid P, Salim SY, Darby T, et al. Effects of anti-
inflammatory therapy on bursting pressure of colonic
anastomosis in murine dextran sulfate sodium induced
colitis. Scand J Gastroenterol 2015; 50: 991–1001.
20. Hardy RS, Doig CL, Hussain Z, et al. 11beta-hydroxys-
teroid dehydrogenase type 1 within muscle protects
against the adverse effects of local inflammation.
J Pathol 2016; 240: 472–483.
21. Assas BM, Levison SE, Little M, et al. Anti-inflamma-
tory effects of infliximab in mice are independent of
tumour necrosis factor alpha neutralization. Clin Exp
Immunol 2017; 187: 225–233.
22. Shealy DJ, Wooley PH, Emmell E, et al. Anti-TNF-alpha
antibody allows healing of joint damage in polyarthritic
transgenic mice. Arthritis Res 2002; 4: R7.
23. Taylor PC, Peters AM, Paleolog E, et al. Reduction of
chemokine levels and leukocyte traffic to joints by tumor
necrosis factor alpha blockade in patients with rheuma-
toid arthritis. Arthritis Rheum 2000; 43: 38–47.
24. Van den Brande JM, Koehler TC, Zelinkova Z, Bennink
RJ, et al. Prediction of antitumour necrosis factor clinical
efficacy by real-time visualisation of apoptosis in patients
with Crohn’s disease. Gut 2007; 56: 509–517.
25. Marmenout A, Fransen L, Tavernier J, et al. Molecular
cloning and expression of human tumor necrosis factor
and comparison with mouse tumor necrosis factor. Eur J
Biochem 1985; 152: 515–522.
26. Ermolova NV, Martinez L, Vetrone SA, et al. Long-term
administration of the TNF blocking drug Remicade
(cV1q) to mdx mice reduces skeletal and cardiac muscle
fibrosis, but negatively impacts cardiac function.
Neuromuscul Disord 2014; 24: 583–595.
27. Stokes WS. Humane endpoints for laboratory animals
used in regulatory testing. ILAR J 2002; 43(Suppl):
S31–S38.
28. Cheng J, Turksen K, Yu QC, Schreiber H, Teng M and
Fuchs E. Cachexia and graft-vs-host-disease-type skin
changes in keratin promoter-driven TNF alpha trans-
genic mice. Genes Dev 1992; 6: 1444–1456.
29. Deboer MD. Animal models of anorexia and cachexia.
Expert Opin Drug Discov 2009; 4: 1145–1155.
Re´sume´
Des mode`les transge´niques TNFa de polyarthrite tels que la souris TNFARE se sont re´ve´le´s pre´cieux pour
de´limiter les aspects de la pathophysiologie des maladies inflammatoires chez les humains.
Malheureusement, l’apparition de l’inflammation et la destruction des articulations chez ces mode`les com-
promet gravement la gestion de la reproduction. Nous avons cherche´ a` savoir si un traitement de´ple´tif TNF a
par « Infliximab » pourrait constituer une nette ame´lioration pour la reproduction de routine. Les re´sultats
cliniques de l’inflammation des articulations ont e´te´ e´value´s chez les maˆles TNFARE recevant soit de
l’Infliximab (10 mg/kg) soit une solution saline par injection intrape´ritone´ale deux fois par semaine.
L’histologie des articulations et la morphologie des os ont e´te´ respectivement e´value´es par une analyse
histologique et par micro-scanner. L’analyse de la reproduction a e´te´ re´alise´e re´trospectivement chez les
maˆles TNFARE avant et apre`s l’administration re´gulie`re d’infliximab. Les re´sultats cliniques d’inflammation
ont e´te´ re´duits significativement chez les maˆles TNFDRE recevant de l’Infliximab (controˆle 6.6 AU þ 0.88
contre infliximab, 4.4 AU 1.4; p< 0.05), tandis que les mesures d’invasion du pannus et de l’e´rosion des
os par histologie et micro-scanner ont e´te´ nettement re´duites. Chez les groupes reproducteurs, les maˆles
TNFARE recevant des injections d’infliximab ont engendre´s plus de porte´es pendant leur dure´e de vie
reproductive (controˆle 1.69 0.22 contre infliximab, 3.00 0.19; p< 0.005). Avant l’infliximab, les maˆles
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TNFARE avaient en outre 26% de risques de ne pas pouvoir se reproduire. Ce risque a e´te´ re´duit de 7% apre`s
l’administration d’Infliximab. Cette e´tude est la premie`re a` rapporter que l’administration re´gulie`re
d’Infliximab est efficace pour supprimer l’activite´ de la maladie et pour ame´liorer le bien-eˆtre des animaux
TNFARE. De plus, nous avons montre´ que l’infliximab est tre`s efficace pour ame´liorer le comportement
reproductif et pour augmenter le nombre de porte´es engendre´es par les maˆles TNFARE.
Abstract
Transgene TNFa-gestu¨tzte Polyarthritismodelle wie die transgene TNFARE Maus haben sich zur Darstellung
der Pathophysiologie entzu¨ndlicher Krankheiten des Menschen als a¨ußerst wertvoll erwiesen. Leider stellt
das Auftreten von Gelenkzersto¨rung und -entzu¨ndung bei diesen Modellen eine erhebliche Beeintra¨chtigung
des Zuchtmanagements dar. Wir untersuchten, ob TNFa-Blocker-Therapie eine wesentliche Verbesserung
routinema¨ßiger Zucht bewirken kann. Klinische Gelenkentzu¨ndungswerte wurden bei TNFARE Ma¨nnchen
untersucht, denen entweder Infliximab (10 mg/kg) oder Salzlo¨sung mittels zwei Mal wo¨chentlich erfolgender
intraperitonealer Injektion verabreicht wurde. Gelenkhistologie und Knochenmorphologie wurden jeweils
durch histologische Analyse und Mikro-CT bewertet. Die Zuchtanalyse wurde retrospektiv bei TNFARE
Ma¨nnchen vor und nach dem regelma¨ßigen Einsatz von Infliximab untersucht. Klinische Entzu¨ndungswerte
waren bei TNFARE Ma¨nnchen, die Infliximab erhielten, signifikant reduziert (Kontrolle 6.6 AU 0.88 versus
Infliximab, 4.4 AU 1.4; p< 0.05), wa¨hrend mittels Histologie und Mikro-CT gewonnene Messwerte von
Pannusbildung und Knochenerosion deutlich reduziert waren. In den Zuchtgruppen zeugten TNFARE
Ma¨nnchen, die Infliximab erhielten, mehr Wu¨rfe wa¨hrend ihrer Zuchtdauer (Kontrolle 1.69 0.22 versus
Infliximab, 3.00 0.19; p< 0.005). Zudem bestand bei TNFARE Ma¨nnchen vor Infliximab-Erhalt ein 26%-
iges Risiko, keinen Nachwuchs zu zeugen. Nach Infliximab-Einsatz sank dieser Wert auf 7%. Mit dieser
Studie wird erstmals berichtet, dass regelma¨ßige Infliximab-Gabe eine Hemmung der Krankheitsaktivita¨t
und eine Verbesserung des Wohlbefindens von TNFARE Tieren bewirkt. Außerdem wurde gezeigt, dass
Infliximab ho¨chst wirksam zur Verbesserung des Zuchtverhaltens und zur Erho¨hung der Zahl der von
TNFARE Ma¨nnchen gezeugten Wu¨rfe beitra¨gt.
Resumen
Los modelos transge´nicos de poliartritis impulsados por TNFa como el rato´n TNFARE han demostrado ser
muy valiosos para delinear aspectos de la patofisiologı´a de enfermedades inflamatorias en humanos.
Lamentablemente, el principio de destruccio´n de articulaciones e inflamacio´n en estos modelos representa
un detrimento significativo para la gestio´n de crı´a. Examinamos si la terapia de agotamiento de TNFa
‘‘Infliximab’’ puede representar un refinamiento significativo en la crı´a rutinaria. Se evaluaron distintas
puntuaciones clı´nicas de inflamacio´n de articulaciones en machos TNFARE que recibı´an Infliximab (10 mg/
kg) o salina dos veces a la semana mediante inyeccio´n intraperitoneal. La histologı´a de las articulaciones y la
morfologı´a o´sea fueron evaluadas mediante ana´lisis histolo´gicos y micro-CT respectivamente. Se examinaron
ana´lisis de la crı´a retrospectivamente en machos TNFARE antes y despue´s de la introduccio´n regular de
Infliximab. Las puntuaciones clı´nicas de inflamacio´n se redujeron significativamente en los machos TNFARE
que recibı´an Infliximab (control 6.6 AU 0.88 versus Infliximab, 4.4 AU 1.4; p< 0.05), mientras que las
medidas de invasio´n de pannus y erosio´n o´sea mediante histologı´a y micro-CT se redujeron significativa-
mente. En los grupos de crı´a, los machos TNFARE que recibı´an inyecciones de Infliximab crearon ma´s
camadas en su vida u´til de crianza (control 1.69 0.22 versus Infliximab, 3.00 0.19; p< 0.005). Asimismo,
antes de Infliximab, los machos TNFARE tuvieron un 26% de riesgo de no poder crear ninguna camada. Esto
se redujo en un 7% tras la introduccio´n de Infliximab. Este es el primer estudio en demostrar que la admin-
istracio´n regular de Infliximab resulta eficaz para suprimir la actividad de enfermedades y para mejorar el
bienestar de animales TNFARE. Asimismo, hemos demostrado que Infliximab es altamente eficaz para
mejorar el comportamiento reproductor y para aumentar el nu´mero de camadas creadas por machos
TNFARE.
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